Fig. 1. Current approaches for targeting pathways in NF1-associated tumorigenesis. Inhibitors of RAF, MEK, and ERK specifically target the MAPK pathway. In contrast, mTOR inhibitors focus on the PI3K/AKT/mTOR pathway. Both receptor tyrosine kinase (RTK) inhibitors and SHP2 inhibitors influence both pathways.
© 2024 Korean Society of Medical Genetics and Genomics